LY2523355
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Leukemia
Conditions
Acute Leukemia
Trial Timeline
Jun 1, 2008 → Feb 1, 2011
NCT ID
NCT01214655About LY2523355
LY2523355 is a phase 1 stage product being developed by Eli Lilly for Acute Leukemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01214655. Target conditions include Acute Leukemia.
What happened to similar drugs?
20 of 20 similar drugs in Acute Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01214655 | Phase 1 | Terminated |
Competing Products
20 competing products in Acute Leukemia